Intermittent rifampicin therapy in lepromatous leprosy

Area of Science:

• Dermatology
• Infectious Diseases
• Pharmacology

Background:

• Leprosy treatment traditionally relies on Dapsone (DDS).
• Intermittent Rifampicin (RFP) regimens are explored to enhance efficacy and combat resistance.
• Evaluating novel drug combinations is crucial for improving patient outcomes.

Purpose of the Study:

• To assess the efficacy and safety of intermittent Rifampicin combined with daily Dapsone for treating leprosy.
• To compare this regimen against Dapsone monotherapy.
• To identify potential adverse effects of the combined intermittent Rifampicin and Dapsone regimen.

Main Methods:

• A double-blind, randomized controlled trial was conducted.
• Twenty untreated leprosy patients received either weekly 900 mg Rifampicin plus daily 100 mg Dapsone or placebo plus daily 100 mg Dapsone for six weeks.
• Outcomes were evaluated over a nine-month follow-up, including mouse foot pad tests.

Main Results:

• The intermittent Rifampicin plus Dapsone regimen demonstrated superior efficacy compared to Dapsone alone.
• Treatment outcomes were comparable to daily Rifampicin regimens.
• No major adverse events were noted, though Erythema Nodosum Leprosum (ENL) incidence was slightly elevated in the treatment group.

Conclusions:

• Intermittent Rifampicin administration alongside daily Dapsone offers an effective leprosy treatment strategy.
• This regimen shows promise as an alternative to daily Rifampicin, potentially improving patient compliance and reducing drug burden.
• Careful monitoring for ENL is recommended when using this treatment approach.